Investors Advised to Act on Capricor Therapeutics Issues
Faruqi & Faruqi, LLP, a prominent national securities law firm, is focusing on the recent developments regarding Capricor Therapeutics, Inc. (NASDAQ: CAPR). With ongoing investigations into potential claims, the firm is inviting investors who have experienced financial losses to engage proactively and seek information about their rights and options regarding legal recourse.
Who Should Reach Out?
If you have acquired securities from Capricor during the relevant period, it is crucial to reach out and discuss your situation. Faruqi & Faruqi has expressed that individuals who purchased shares between October 9, 2024, and July 10, 2025, should particularly consider contacting the firm. The upcoming deadlines may require swift action to ensure your voice is heard in potential legal proceedings.
Understanding the Securities Class Action
At the heart of these investigations is the concern that Capricor's executives might have breached federal securities laws. The allegations suggest that misleading information was disseminated regarding the company's lead product, deramiocel, a cell therapy aimed at treating certain neuromuscular conditions. Investors have raised concerns that they were not fully informed about the drug’s regulatory hurdles and the associated clinical data setbacks.
Recent Developments
On a significant date in July 2025, Capricor announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), which denied approval of their Biologics License Application (BLA). This announcement triggered a sudden and steep decline in the stock price, indicating investor reactions to the news and the reality of the company's challenges.
What Investors Should Do Next
Investors need to be aware of their rights regarding the legal actions being initiated. In a securities class action, the lead plaintiff plays a critical role in guiding the proceedings. Being appointed as lead plaintiff signifies a commitment to represent the class effectively and could be beneficial during the recovery process. In essence, your decision to step forward won't affect your recovery unless you choose not to participate.
Encouragement for Whistleblowers and Individuals with Information
Faruqi & Faruqi not only reaches out to those affected by the financial troubles of Capricor but also welcomes insights from whistleblowers and former employees. Those who might have pertinent information about the company’s operations or internal communications may play a significant part in shedding light on the issues at hand.
How Faruqi & Faruqi Supports Investors
Faruqi & Faruqi is dedicated to assisting investors in navigating the complexities of legal proceedings. Have the comfort and confidence of working with a firm that has successfully recovered substantial amounts for clients over its years of operation. If you need guidance, please feel free to reach out directly or check their website for detailed information related to the ongoing class action against Capricor Therapeutics.
Frequently Asked Questions
1. What should I do if I invested in Capricor?
If you invested in Capricor between the specified dates, contact Faruqi & Faruqi for guidance on your rights and options.
2. How can I participate in the class action?
To participate, you may need to contact the law firm directly to understand the steps involved in becoming part of the lawsuit.
3. What is the deadline for action?
Investors are reminded about the specifics of deadlines to act as lead plaintiffs, crucial for those considering to step forward.
4. What information should I provide to the law firm?
It's helpful to provide your investment details, including dates and amounts, along with any documentation you may have.
5. Is taking legal action necessary?
Engaging in legal action may offer the possibility of financial recovery, but it is important to assess your individual situation and risks.
